CN118159558A - 抗dll3抗体和其用途 - Google Patents
抗dll3抗体和其用途 Download PDFInfo
- Publication number
- CN118159558A CN118159558A CN202280071949.3A CN202280071949A CN118159558A CN 118159558 A CN118159558 A CN 118159558A CN 202280071949 A CN202280071949 A CN 202280071949A CN 118159558 A CN118159558 A CN 118159558A
- Authority
- CN
- China
- Prior art keywords
- seq
- amino acid
- acid sequence
- variable region
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1054—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163240216P | 2021-09-02 | 2021-09-02 | |
| US63/240,216 | 2021-09-02 | ||
| PCT/US2022/042451 WO2023034566A1 (en) | 2021-09-02 | 2022-09-02 | Anti-dll3 antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118159558A true CN118159558A (zh) | 2024-06-07 |
Family
ID=85412872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280071949.3A Pending CN118159558A (zh) | 2021-09-02 | 2022-09-02 | 抗dll3抗体和其用途 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240368269A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4396224A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024534892A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118159558A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022337142A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3230628A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023034566A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202421189A (zh) * | 2022-08-22 | 2024-06-01 | 美商雅博得樂醫療公司 | 用於標靶性放射性同位素療法之多價免疫結合物 |
| CN121293357A (zh) | 2022-08-22 | 2026-01-09 | 雅博得乐医疗公司 | Dll3结合分子及其用途 |
| WO2025061132A1 (en) * | 2023-09-21 | 2025-03-27 | Concept To Medicine Biotech Co., Ltd. | Anti-dll3 antibodies and uses thereof |
| TW202600599A (zh) * | 2024-03-11 | 2026-01-01 | 大陸商樂普生物科技股份有限公司 | 抗dll3抗體及其用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2530091T3 (pl) * | 2010-01-29 | 2018-08-31 | Chugai Seiyaku Kabushiki Kaisha | Przeciwciało przeciwko dll3 |
| EP2598532B1 (en) * | 2010-07-30 | 2017-07-12 | Gianluca Moroncini | Epitopes of the human pdgf receptor able to bind human auto-antibodies, antibodies and uses thereof |
| ES2886123T3 (es) * | 2012-01-31 | 2021-12-16 | Regeneron Pharma | Anticuerpos anti-asic1 y usos de los mismos |
| CN107922487A (zh) * | 2015-03-06 | 2018-04-17 | 索伦托治疗有限公司 | 结合jag1的抗体治疗剂 |
| EP3337517A4 (en) * | 2015-08-20 | 2019-04-17 | Abbvie Stemcentrx LLC | ANTI-DLL3 ANTIBODY AGGREGATE CONJUGATES AND METHOD OF USE |
| AU2016332900C1 (en) * | 2015-09-29 | 2024-07-04 | Amgen Inc. | ASGR inhibitors |
| WO2019079762A1 (en) * | 2017-10-20 | 2019-04-25 | Children's National Medical Center | METHODS OF DISCOVERING ANTIBODIES USING TRANSCRIPTOMES AND COMPOSITIONS DERIVED THEREFROM |
| US20220025037A1 (en) * | 2018-04-03 | 2022-01-27 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting dll3, and use thereof |
| TWI848953B (zh) * | 2018-06-09 | 2024-07-21 | 德商百靈佳殷格翰國際股份有限公司 | 針對癌症治療之多特異性結合蛋白 |
| AU2019414968A1 (en) * | 2018-12-27 | 2021-08-12 | Gigagen, Inc. | Anti-PD-1 binding proteins and methods of use thereof |
| US12441789B2 (en) * | 2019-07-11 | 2025-10-14 | Memorial Sloan Kettering Cancer Center | DLL3-targeting antibodies and uses thereof |
| EP4065601A1 (en) * | 2019-11-25 | 2022-10-05 | Mabloc, LLC | Anti-yellow fever virus antibodies, and methods of their generation and use |
-
2022
- 2022-09-02 JP JP2024513940A patent/JP2024534892A/ja active Pending
- 2022-09-02 CN CN202280071949.3A patent/CN118159558A/zh active Pending
- 2022-09-02 WO PCT/US2022/042451 patent/WO2023034566A1/en not_active Ceased
- 2022-09-02 CA CA3230628A patent/CA3230628A1/en active Pending
- 2022-09-02 EP EP22865604.7A patent/EP4396224A4/en active Pending
- 2022-09-02 AU AU2022337142A patent/AU2022337142A1/en active Pending
-
2024
- 2024-02-28 US US18/589,762 patent/US20240368269A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3230628A1 (en) | 2023-03-09 |
| EP4396224A4 (en) | 2025-11-12 |
| AU2022337142A1 (en) | 2024-03-07 |
| US20240368269A1 (en) | 2024-11-07 |
| JP2024534892A (ja) | 2024-09-26 |
| EP4396224A1 (en) | 2024-07-10 |
| WO2023034566A1 (en) | 2023-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2500250C (en) | Humanized anti-granulocyte mn-3 antibody and uses thereof | |
| US7183388B2 (en) | Anti-MUC-1 single chain antibodies for tumor targeting | |
| CA2447695C (en) | Modified antibodies to prostate-specific membrane antigen and uses thereof | |
| KR101143035B1 (ko) | 단클론 항체 hPAM4 | |
| JP5138867B2 (ja) | α−フェトタンパク質Immu31抗体および融合タンパク質ならびにその使用方法 | |
| KR101228124B1 (ko) | 단클론 항체 pam4 및 췌장암의 진단 및 치료를 위한이들의 용도 | |
| US20240368269A1 (en) | Anti-dll3 antibodies and uses thereof | |
| US20050118165A1 (en) | Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor | |
| JP2025156278A (ja) | Dll3をターゲッティングする抗体とその使用 | |
| JP2024534892A5 (cg-RX-API-DMAC7.html) | ||
| CA2558718C (en) | Anti-human tenascin monoclonal antibody | |
| CA2555306A1 (en) | Humanized antibody | |
| JP2021511068A (ja) | Centrin−1に対する抗体、作製方法、及びその使用 | |
| WO2021229104A1 (en) | Anti-cd38 single-domain antibodies in disease monitoring and treatment | |
| US20240262910A1 (en) | Anti-cd33 antibodies and uses thereof | |
| EP4721765A1 (en) | Bi-functionalized antibody conjugates against the endothelin receptor b | |
| US20230190968A1 (en) | Anti-cd38 single-domain antibodies in disease monitoring and treatment | |
| WO2025255296A1 (en) | Antibodies targeting mesothelin and uses thereof | |
| CN120813379A (zh) | 靶向l1cam的抗体及其用途 | |
| IL165752A (en) | Chimeric monoclonal antibody pam4, a conjugate comprising it and an antibody comprising the same or fragments thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |